CME

Rapid Rule Out of AMI: Taking Cardiac Testing to the Next Level

Authors: David Morrow, MD; Christian Mueller, MD; Bertil Lindahl, MD, PhD; Christopher R deFilippi, MD
CME Released: 1/22/2016
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 1/22/2017

Target Audience and Goal Statement

This activity is intended for cardiologists, emergency medicine physicians, and primary care physicians.

The goal of this activity is to help clinicians understand recent clinical trial data on the use biomarkers, such as high-sensitivity cardiac troponin levels, to rapidly exclude acute myocardial infarction (AMI).

Upon completion of this activity, participants will be able to:

Evaluate the clinical need for tools and biomarkers that rapidly and reliably diagnose or rule out acute myocardial infarction
Assess recent clinical trial data on the use of biomarkers such as hs-troponin to rapidly exclude AMI

Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator(s)

David A. Morrow, MD, MPH

Associate Professor of Medicine, Harvard Medical School; Director, Levine Cardiac Intensive Care Unit, Brigham and Women's Hospital, Boston, Massachusetts

Disclosures

Disclosure: David A. Morrow, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BG Medicine; Critical Diagnostics; Genentech, Inc.; Gilead Sciences, Inc.; Instrumentation Laboratory; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck & Co., Inc.; Roche Dignostics; SERVIER
Received grants for clinical research from: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Athera Biotechnologies AB; Beckman Coulter, Inc.; BG Medicine; Bristol-Myers Squibb Company; BÜHLMANN Laboratories; Daichii Sankyo, Inc.; Eisai Co., Ltd; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Lilly; Merck & Co., Inc.; Nanosphere, Inc.; Novartis Pharmaceuticals Corporation; Ortho-Clinical Diagnostics, Inc.; Pfizer Inc; Randox Laboratories Ltd.; Roche Diagnostics; Sanofi; Siemens AG; Singulex

Dr Morrow does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Morrow does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelist(s)

Christian Mueller, MD

Professor, University Hospital, Basel, Switzerland

Disclosures

Disclosure: Christian Mueller, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BG Medicine; Brahms; Cardiorentis AG; Novartis Pharmaceuticals Corporation; Roche
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Brahms; Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: Abbott Laboratories; Brahms; Roche; Siemens AG; Singulex

Dr Mueller does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Mueller does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Bertil Lindahl, MD, PhD

Professor, Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden

Disclosures

Disclosure: Bertil Lindahl, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: bioMérieux; Fiomi Diagnostics AB; Philips Healthcare; Roche
Served as a speaker or a member of a speakers bureau for: Thermo Fisher Scientific Inc.
Received grants for clinical research from: bioMérieux; Fiomi Diagnostics AB

Dr Lindahl does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Lindahl does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Christopher deFilippi, MD

Associate Professor of Medicine, University of Maryland School of Medicine, Baltimore, Maryland

Disclosures

Disclosure: Christopher deFilippi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: HDL Therapeutics; Siemens AG; Roche Diagnostics
Served as a speaker or a member of a speakers bureau for: Radiometer Medical ApS
Received grants for clinical research from: Alere; BG Medicine; Critical Diagnostics; Roche Diagnostics

Dr deFilippi does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr deFilippi does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

Ileana L. Piña, MD, MPH

Professor of Medicine and Epidemiology & Population Health, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York

Disclosures

Disclosure: Ileana L. Piña, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: FDA; GE Healthcare; Novartis Pharmaceuticals Corporation
Served as a speaker or a member of a speakers bureau for: Otsuka Pharmaceuticals

Gary Michael Felker, MD, MHS

Associate Professor of Medicine; Chief-Heart Failure Section, Director-Clinical Research Unit, Director-Heart Failure Research, Duke University Medical Center, Durham, North Carolina

Disclosures

Disclosure: Gary Michael Felker, MD, MHS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen, Inc.; Celladon; Novartis Pharmaceuticals Corporation; Roche; Singulex; St Jude Medical; Trevana, Inc.; Zensun Sci. and Tech. Co., Ltd.
Received grants for clinical research from: Amgen, Inc.; Roche; Otsuka Pharmaceuticals

W. Brian Gibler, MD

Professor, Department of Emergency Medicine, University of Cincinnati College of Medicine; President and CEO, University of Cincinnati Medical Center, Cincinnati, Ohio

Disclosures

Disclosure: W. Brian Gibler, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Lilly
Owns stock, stock options, or bonds from: Siloam Biosciences

Allan S. Jaffe, MD

Professor of Medicine and Professor of Laboratory Medicine and Pathology, Mayo Clinic and Medical School; Consultant in Cardiology and Laboratory Medicine and Pathology and Chair, Clinical Laboratory Services, Mayo Clinic, Rochester, Minnesota

Disclosures

Disclosure: Allan S Jaffe, MD, has disclosed the following relevant financial information:
Served as a speaker or a member of a speakers bureau for: Abbott Laboratories; Amgen, Inc.; Beckman Coulter, Inc.; Critical Diagnostics; diaDexus, Inc.; Ortho-Clinical Diagnostics; Radiometer Medical ApS; Roche

James L. Januzzi, MD

Professor of Medicine, Harvard Medical School; Roman W. DeSanctis Endowed Clinical Scholar, Massachusetts General Hospital, Boston, Massachusetts

Disclosures

Disclosure: James L. Januzzi, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Critical Diagnostics; Roche
Received grants for clinical research from: BG Medicine; Critical Diagnostics; Roche; Thermo Fisher Scientific Inc.

David A. Morrow, MD, MPH

Disclosures

As listed above.

L. Kristin Newby, MD, MHS

Professor of Medicine, Cardiology, Duke University School of Medicine; Co-Director, Duke Cardiac Care Unit, Duke University Medical Center, Durham, North Carolina

Disclosures

Disclosure: L Kristin Newby, MD, MHS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Daiichi Sankyo, Inc.; Genentech, Inc.; Janssen Pharmaceuticals Corporation, L.P.; Lilly; Navigant; Novartis Pharmaceuticals Corporation; Roche
Received grants for clinical research from: Amylin Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Merck & Co., Inc.; Murdock Study; National Heart, Lung, and Blood Institute

Editor(s)

Joy Marko, MS, FNP-C, CCMEP

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Joy Marko, MS, FNP-C, CCMEP, has disclosed no relevant financial relationships.

CME Reviewer(s)

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Received grants for clinical research from: Otsuka Pharmaceutical Co., Ltd.
Served as an advisor or consultant for: Thoratec Corporation; HeartWare International, Inc.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Cardiology

CME

Rapid Rule Out of AMI: Taking Cardiac Testing to the Next Level

Authors: David Morrow, MD; Christian Mueller, MD; Bertil Lindahl, MD, PhD; Christopher R deFilippi, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 1/22/2016

Valid for credit through: 1/22/2017

processing....

This feature requires the newest version of Flash. You can download it here.

CME Information Download Slides

Additional Resources

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator(s)

David A. Morrow, MD, MPH

Panelist(s)

Christian Mueller, MD

Bertil Lindahl, MD, PhD

Christopher deFilippi, MD

Steering Committee

Ileana L. Piña, MD, MPH

Gary Michael Felker, MD, MHS

W. Brian Gibler, MD

Allan S. Jaffe, MD

James L. Januzzi, MD

David A. Morrow, MD, MPH

L. Kristin Newby, MD, MHS

Editor(s)

Joy Marko, MS, FNP-C, CCMEP

CME Reviewer(s)

Nafeez Zawahir, MD

Peer Reviewer

CME

Rapid Rule Out of AMI: Taking Cardiac Testing to the Next Level

Target Audience and Goal Statement

Disclosures

Moderator(s)

David A. Morrow, MD, MPH

Panelist(s)

Christian Mueller, MD

Bertil Lindahl, MD, PhD

Christopher deFilippi, MD

Steering Committee

Ileana L. Piña, MD, MPH

Gary Michael Felker, MD, MHS

W. Brian Gibler, MD

Allan S. Jaffe, MD

James L. Januzzi, MD

David A. Morrow, MD, MPH

L. Kristin Newby, MD, MHS

Editor(s)

Joy Marko, MS, FNP-C, CCMEP

CME Reviewer(s)

Nafeez Zawahir, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Rapid Rule Out of AMI: Taking Cardiac Testing to the Next Level